La Jolla Pharmaceutical Company Appoints Lakhmir S. Chawla, M.D., as Chief Medical Officer
April 27 2015 - 8:00AM
Business Wire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or
La Jolla), a leader in the development of innovative therapies
intended to significantly improve outcomes in patients suffering
from life-threatening diseases, today announced that Lakhmir S.
Chawla, M.D., will be joining the Company as Chief Medical Officer,
effective July 1, 2015.
“Dr. Chawla brings to La Jolla a wealth of knowledge and
experience, including very relevant expertise in the areas of
critical care medicine and nephrology,” said George F. Tidmarsh,
M.D., Ph.D., President and Chief Executive Officer of La Jolla. “We
are excited to welcome him to La Jolla’s executive team at this
important stage of our growth and development.”
“I am delighted to be joining this highly innovative company,”
added Dr. Chawla. “La Jolla has assembled an exceptional team of
professionals, and I look forward to working with them in
developing novel therapeutics for life-threatening diseases.”
Dr. Chawla is currently an Associate Professor of Medicine at
the George Washington University, where he has dual appointments in
the Department of Anesthesiology and Critical Care Medicine and in
the Department of Medicine, Division of Renal Diseases and
Hypertension. Dr. Chawla is also currently the Chief of the
Division of Intensive Care Medicine at the Washington D.C. Veterans
Affairs Medical Center. During his tenure at George Washington, Dr.
Chawla was the designer and lead investigator of a pilot study
called the ATHOS (Angiotensin
II for the Treatment of
High Output Shock) trial. Data from the ATHOS trial was
published in the medical journal Critical Care during 2014 and
demonstrated the utility of angiotensin II in patients with severe
shock. These data were also used in support of the initiation of La
Jolla’s ATHOS 3 trial, a Phase 3 clinical trial of LJPC-501, La
Jolla’s proprietary formulation of angiotensin II, for the
treatment of catecholamine-resistant hypotension, which was
initiated in March 2015.
Dr. Chawla is an internationally renowned expert in the field of
acute kidney injury (AKI) and is an active investigator in the
fields of inflammation and AKI, AKI biomarkers, AKI risk
prediction, chronic kidney disease caused by AKI and AKI
therapeutics. In addition, Dr. Chawla is an active investigator in
shock, inflammation and extracorporeal therapies, including:
continuous renal replacement therapy, dialysis and albumin
dialysis. Dr. Chawla is also the author of over 100 peer-reviewed
publications and an Associate Editor for the Clinical Journal of
the American Society of Nephrology.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company
focused on the discovery, development and commercialization of
innovative therapies intended to significantly improve outcomes in
patients suffering from life-threatening diseases. The Company has
four product candidates in development. LJPC-501 is La Jolla’s
proprietary formulation of angiotensin II for the potential
treatment of catecholamine-resistant hypotension and hepatorenal
syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor
for the potential treatment of chronic kidney disease. LJPC-1010,
La Jolla’s second-generation galectin-3 inhibitor, is a more potent
and purified derivative of GCS-100 that can be delivered orally for
the potential treatment of nonalcoholic steatohepatitis and other
diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s
novel formulation of hepcidin for the potential treatment of
conditions characterized by iron overload, such as hemochromatosis
and beta thalassemia. For more information on La Jolla, please
visit www.ljpc.com.
Forward-Looking Statement Safe Harbor
This document contains forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
These statements relate to future events or the Company’s future
results of operations. These statements are only predictions and
involve known and unknown risks, uncertainties and other factors,
which may cause actual results to be materially different from
these forward-looking statements. The Company cautions readers not
to place undue reliance on any such forward-looking statements,
which speak only as of the date they were made. Certain of these
risks, uncertainties, and other factors are described in greater
detail in the Company's filings with the U.S. Securities and
Exchange Commission (SEC), all of which are available free of
charge on the SEC's web site http://www.sec.gov. These risks include, but are
not limited to, risks relating to: the timing for the filing of an
Investigational New Drug Application, commencement of clinical
studies and the anticipated timing for completion of such studies;
the success of future development activities for LJPC-501, GCS-100,
LJPC-1010 and LJPC-401; and potential indications for which
LJPC-501, GCS-100, LJPC-1010 and LJPC-401 may be developed.
Subsequent written and oral forward-looking statements attributable
to the Company or to persons acting on its behalf are expressly
qualified in their entirety by the cautionary statements set forth
in the Company's reports filed with the SEC. The Company expressly
disclaims any intent to update any forward-looking statements.
La Jolla Pharmaceutical CompanyGeorge F. Tidmarsh, M.D.,
Ph.D.President & Chief Executive OfficerPhone: (858)
207-4264Email: gtidmarsh@ljpc.comandDennis M. MulroyChief Financial
OfficerPhone: (858) 433-6839Email: dmulroy@ljpc.com
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Apr 2023 to Apr 2024